BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 20501908)

  • 21. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
    JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
    Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
    J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
    Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
    J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-phase
    Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
    J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
    Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
    J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
    Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
    BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeatability of parametric methods for [
    Verfaillie SC; Golla SS; Timmers T; Tuncel H; van der Weijden CW; Schober P; Schuit RC; van der Flier WM; Windhorst AD; Lammertsma AA; van Berckel BN; Boellaard R
    J Cereb Blood Flow Metab; 2021 Mar; 41(3):569-578. PubMed ID: 32321347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
    McNamee RL; Yee SH; Price JC; Klunk WE; Rosario B; Weissfeld L; Ziolko S; Berginc M; Lopresti B; Dekosky S; Mathis CA
    J Nucl Med; 2009 Mar; 50(3):348-55. PubMed ID: 19223409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic Modeling of the Tau PET Tracer
    Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
    J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.
    Wu KY; Hsiao IT; Chen CS; Chen CH; Hsieh CJ; Wai YY; Chang CJ; Tseng HJ; Yen TC; Liu CY; Lin KJ
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):714-22. PubMed ID: 24233127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tracer-specific reference tissues selection improves detection of
    Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
    Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
    Villemagne VL; Ong K; Mulligan RS; Holl G; Pejoska S; Jones G; O'Keefe G; Ackerman U; Tochon-Danguy H; Chan JG; Reininger CB; Fels L; Putz B; Rohde B; Masters CL; Rowe CC
    J Nucl Med; 2011 Aug; 52(8):1210-7. PubMed ID: 21764791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.
    Huang KL; Lin KJ; Hsiao IT; Kuo HC; Hsu WC; Chuang WL; Kung MP; Wey SP; Hsieh CJ; Wai YY; Yen TC; Huang CC
    PLoS One; 2013; 8(3):e58974. PubMed ID: 23516589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.